InfuSystem Reaffirms 2026 Revenue Growth Guidance Amid Wound Care Expansion
InfuSystem Holdings, Inc. (INFU) has reaffirmed its pro forma revenue growth guidance of 6% to 8% for the year 2026. During the Q3 earnings discussion, management highlighted the successful execution of their profitable growth strategy and emphasized the ongoing scaling of their wound care segment. CEO Carrie Lachance expressed confidence in the company's current trajectory, noting that recent quarterly results demonstrate consistent operational performance. The company continues to focus on expanding its market presence within the wound care sector to drive long-term value.
Tickers: $INFU
Topics: earnings report management commentary profitable growth strategy